In our analyses, both non-small cell lung cancer and head and neck squamous cell carcinoma are HM cancers, and we predict, therefore, that there is a strong likelihood that many other HM cancers such as skin cutaneous melanoma, bladder urothelial carcinoma and lung adenocarcinoma may also respond to drugs that target the EGFR signalling pathway. Here, EGFR is linked to lung adenocarcinoma.